# US 2026/0130984 A1 · Highly networked immunogen composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0130984 A1
- Document ID: US20260130984A1
- Status: Published application
- Kind: A1
- Application number: 19/448,540
- Filed: 2026-01-14
- Published: 2026-05-14
- Earliest claimed: 2019-03-12
- Assignees: The General Hospital Corporation; Massachusetts Eye and Ear Infirmary
- Applicants: The General Hospital Corporation; Massachusetts Eye and Ear Infirmary
- Inventors: Bruce WALKER; Gaurav D. GAIHA; Elizabeth ROSSIN
- Web page: https://patentgrep.com/patent/US20260130984A1

## CPC

- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- C07K 14/005: from viruses
- A61K 39/12: Viral antigens
- A61P 31/18: for HIV
- A61P 37/04: Immunostimulants
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- C12N 2740/16022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12N 2740/16222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/16234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/36143: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A method of preventing or treating HIV in a subject includes selecting two or more HIV CTL epitopes from an HIV proteome that have a network score that meets a threshold value. The network score for a given epitope can be determined by generating at least one network representing protein structure, calculating a set of network parameters, combining the network parameters to determine a network score for each amino acid residue in the protein structure, generating a network score for each of a plurality of epitopes as a weighted linear combination of the amino acid residues of the epitopes, and selecting two or more epitopes according to their network score. An effective amount of a T cell immunogen composition and a pharmaceutically acceptable carrier is administered to the subject. The T cell immunogen composition includes the two or more selected HIV CTL epitopes.

## Claims

### Claim 1

A multi-epitope T cell immunogen composition comprising two or more highly networked HIV CTL epitopes, wherein the two or more highly networked HIV CTL epitopes each have a network score of at least 3.04.

### Claim 2 (depends on 1)

The multi-epitope T cell immunogen composition of claim 1, wherein the highly networked HIV CTL epitope is a HIV CTL epitope variant having at least about 65% to about 99% homology to a Group M consensus HIV CTL epitope.

### Claim 3 (depends on 1)

The multi-epitope T cell immunogen composition of claim 1, comprising two highly networked HIV CTL epitopes restricted by HLA-B*57.

### Claim 4 (depends on 3)

The multi-epitope T cell immunogen composition of claim 3, wherein the two highly networked HIV CTL epitopes are HLA-B*57 KAFSPEVIMPF (KF11) (SEQ ID NO:201) and HLA-B*57 TSTLQEQIGW (TW10) (SEQ ID NO:202).

### Claim 5 (depends on 3)

The multi-epitope T cell immunogen composition of claim 3, wherein the amino acid sequence of the highly networked HIV CTL epitope has at least about 65% to about 99% homology to the amino acid sequence of HLA-B*57 KF11 or HLA-B*57 TW10.

### Claim 6 (depends on 1)

The multi-epitope T cell immunogen composition of claim 1, further comprising HIV CTL epitopes HLA-A*02 SLYNTVATL (SL9) (SEQ ID NO:20), HLA-A*02 ILKEPVHGV (IV9) (SEQ ID NO:19) and HLA-B*57 HTQGYFPDW (HW9) (SEQ ID NO: 209).

### Claim 7 (depends on 1)

The multi-epitope T cell immunogen composition of claim 1, comprising three highly networked HIV CTL epitopes restricted by HLA-A*02.

### Claim 8 (depends on 7)

The multi-epitope T cell immunogen composition of claim 7, wherein the three highly networked HIV CTL epitopes are HLA-A*02 KLTPLCVTL (KL9), HLA-A*02 YVDRFYFTL (YL9), and HLA-A*02 VIYQYMDDL (VL9).

### Claim 9 (depends on 8)

The multi-epitope T cell immunogen composition of claim 8, wherein the amino acid sequence of the highly networked HIV CTL epitope has at least about 65% to about 99% homology to the amino acid sequence of HLA-A*02 KLTPLCVTL (KL9), HLA-A*02 YVDRFYFTL (YL9), or HLA-A*02 VIYQYMDDL (VL9).

### Claim 10 (depends on 1)

The multi-epitope T cell immunogen composition of claim 1, comprising at least ten highly networked HIV CTL epitopes restricted by HLA-A*02, HLA-A*03, HLA-A*11 or HLA-B*07.

### Claim 11 (depends on 10)

The multi-epitope T cell immunogen composition of claim 10, wherein the ten highly networked HIV CTL epitopes are HLA-A*02 YVDRFYKTL (YL9), HLA-A*03 GIPHPAFLK (GK9), HLA-B*07 TPQDLNTML (TL9), HLA-A*11 ACQGVGGPGHK (AK11), HLA-A*02 VL9 VIYQYMDDL (VL9), HLA-A*11 AVDLSHFLK (AK9), HLA-A*02 KLTPLKCVTL (KL9), HLA-B*07 SPRTLNAW (SV9), HLA-A*02 PLTFGWCYKL (PL10), and B*07 TPGPGVRYPL (TL10).

### Claim 12 (depends on 11)

The multi-epitope T cell immunogen composition of claim 11, wherein the amino acid sequence of the highly networked HIV CTL epitope has at least about 65% to about 99% homology to the amino acid sequence of HLA-A*02 YVDRFYKTL (YL9), HLA-A*03 GIPHPAFLK (GK9), HLA-B*07 TPQDLNTML (TL9), HLA-A*11 ACQGVGGPGHK (AK11), HLA-A*02 VL9 VIYQYMDDL (VL9), HLA-A*11 AVDLSHFLK (AK9), HLA-A*02 KLTPLKCVTL (KL9), HLA-B*07 SPRTLNAW (SV9), HLA-A*02 PLTFGWCYKL (PL10), or B*07 TPGPGVRYPL (TL10).

### Claim 13 (depends on 1)

The multi-epitope T cell immunogen composition of claim 1, comprising two highly networked HIV CTL epitopes restricted by HLA-E*101 and HLA-E*103.

### Claim 14 (depends on 13)

The multi-epitope T cell immunogen composition of claim 13, wherein the two highly networked HIV CTL epitopes are selected from HLA-E*101/E*103 SALSEGATP, HLA-E*101/E*103 RMYSPTSIL, HLA-E*101/E*103 RIRTWKSLV, HLA-E*101/E*103 AISPRTLNA, HLA-E*101/E*103 STLQEQIGW, HLA-E*101/E*103 HQAISPRTL and HLA-E*101/E*103 VGGHQAAMQ.

### Claim 15

A method comprising:
selecting two or more HIV CTL epitopes from an HIV proteome, that have a network score that meets a threshold value, the network score for a given epitope being determinable by generating at least one network representing protein structure, calculating a set of network parameters, combining the network parameters to determine a network score for each amino acid residue in the protein structure, and generating the network score for each of a plurality of epitopes as a weighted linear combination of the respective network scores for the amino acid residues of the epitopes; and
administering to the subject a therapeutically effective amount of a T cell immunogen composition and a pharmaceutically acceptable carrier, the T cell immunogen composition including the two or more selected HIV CTL epitopes.

### Claim 16 (depends on 15)

The method of claim 15, wherein the threshold value is 3.06, such that the selected two or more HIV CTL epitopes each have a network score of at least 3.06.

### Claim 17 (depends on 15)

The method of claim 15, wherein the two or more selected HIV CTL epitopes induce de novo cytotoxic T cell responses in the subject.

### Claim 18 (depends on 15)

The method of claim 15, the T cell immunogen composition comprising a recombinant vector.

### Claim 19 (depends on 15)

The method of claim 15, the T cell immunogen composition comprising a viral vector.

### Claim 20 (depends on 19)

The method of claim 19, the viral vector selected from the group consisting of a human adenovirus, a rhesus adenovirus, adeno-associated virus, modified Ankara virus, herpesvirus, and CMV viral vectors.

### Claim 21 (depends on 15)

The method of claim 15, the T cell immunogen composition comprising a nucleic acid.

### Claim 22 (depends on 21)

The method of claim 21, wherein the nucleic acid is selected from the group consisting of DNA, mRNA and replicon RNA.

### Claim 23 (depends on 22)

The method of claim 22, wherein the nucleic acid is loaded into a lipid nanoparticle.

### Claim 24 (depends on 15)

The method of claim 15, the T cell immunogen composition comprising a peptide based T cell immunogen composition.

### Claim 25 (depends on 24)

The method of claim 24, wherein the peptide is loaded into a lipid nanoparticle.

### Claim 26 (depends on 24)

The method of claim 24, wherein the peptide is loaded into dendritic cells.

### Claim 27

A method of preventing HIV infection in a subject, the method comprising:
selecting two or more HIV CTL epitopes from an HIV proteome, that have a network score that meets a threshold value, the network score for a given epitope being determinable by generating at least one network representing protein structure, calculating a set of network parameters, combining the network parameters to determine a network score for each amino acid residue in the protein structure, and generating the network score for each of a plurality of epitopes as a weighted linear combination of the respective network scores for the amino acid residues of the epitopes; and
administering to the subject a prophylactically effective amount of a T cell immunogen composition and a pharmaceutically acceptable carrier, the T cell immunogen composition including the two or more selected HIV CTL epitopes.

### Claim 28 (depends on 27)

The method of claim 27, wherein the selected two or more HIV CTL epitopes have a network score of at least 3.06.

### Claim 29 (depends on 27)

The method of claim 27, wherein the two or more selected HIV CTL epitopes induce de novo cytotoxic T cell responses in the subject.

### Claim 30 (depends on 27)

The method of claim 27, the T cell immunogen composition comprising a recombinant vector.

### Claim 31 (depends on 27)

The method of claim 27, the T cell immunogen composition comprising a viral vector.

### Claim 32 (depends on 27)

The method of claim 27, the viral vector selected from the group consisting of a human adenovirus, a rhesus adenovirus, adeno-associated virus, modified Ankara virus, herpesvirus, and CMV viral vectors.

### Claim 33 (depends on 27)

The method of claim 27, the T cell immunogen composition comprising a nucleic acid.

### Claim 34 (depends on 33)

The method of claim 33, wherein the nucleic acid is selected from the group consisting of DNA, mRNA and replicon RNA.

### Claim 35 (depends on 33)

The method of claim 33, wherein the nucleic acid is loaded into a lipid nanoparticle.

### Claim 36 (depends on 27)

The method of claim 27, the T cell immunogen composition comprising a peptide based T cell immunogen composition.

### Claim 37 (depends on 36)

The method of claim 36, wherein the peptide is loaded into a lipid nanoparticle.

### Claim 38 (depends on 36)

The method of claim 36, wherein the peptide is loaded into dendritic cells.

### Claim 39

A method comprising:
generating at least one network representing protein structure;
calculating a set of network parameters;
combining the network parameters to determine a network score for each amino acid residue in the protein structure;
generating the network score for each of a plurality of epitopes as a weighted linear combination of the respective network scores for the amino acid residues of the epitopes; and
selecting two or more HIV CTL epitopes from an HIV proteome that have a network score that meets a threshold value.

### Claim 40 (depends on 39)

The method of claim 39, wherein the threshold value is 3.06, such that the selected two or more HIV CTL epitopes each have a network score of at least 3.06.

### Claim 41

A method of preventing HIV infection in a subject, the method comprising:
administering to the subject a prophylactically effective amount of a multi-epitope T cell immunogen composition comprising two or more highly networked HIV CTL epitopes, wherein the two or more highly networked HIV CTL epitopes each have a network score of at least 3.06, and a pharmaceutically acceptable carrier, thereby preventing HIV infection in the subject.

### Claim 42

A vector comprising a sequence encoding a highly networked HIV CTL epitope shown in FIG. 21 or FIG. 22, wherein the highly networked HIV CTL epitope has a network score of at least 3.06 in FIG. 21 or FIG. 22.

### Claim 43

A vector comprising a multi-epitope T cell immunogen, wherein the vector comprises a sequence encoding two or more highly networked HIV CTL epitopes, wherein the two or more highly networked HIV CTL epitopes each have a network score from 3.04 to 9.05.

### Claim 44 (depends on 43)

The vector of claim 43, wherein the two or more highly networked HIV CTL epitopes each have a network score of at least 3.06.

### Claim 45 (depends on 42, 43, 44)

The vector of any one of claims 42 to 44, wherein, for each of the highly networked HIV CTL epitopes, the vector comprises an endoplasmic reticulum insertion signal sequence (ERISS).

### Claim 46 (depends on 42, 43, 44, 45)

The vector of any one of claims 42 to 45, wherein the vector comprises a sequence encoding a pan HLA DR-binding epitope (PADRE).

### Claim 47 (depends on 42, 43, 44, 45, 46)

The vector of any one of claims 42 to 46, wherein, for each of the highly networked HIV CTL epitopes, the vector comprises an enzyme cleavage site sequence.

### Claim 48 (depends on 47)

The vector of claim 47, wherein the enzyme cleavage site is a furin cleavage site sequence.

### Claim 49 (depends on 43, 44, 45, 46, 47, 48)

The vector of any one of claims 43 to 48, wherein the sequences encoding the highly networked HIV CTL epitopes are directly linked to each other.

### Claim 50 (depends on 43, 44, 45, 46, 47, 48)

The vector of any one of claims 43 to 48, wherein the sequences encoding the two or more highly networked HIV CTL epitopes are linked by a linker sequence.

### Claim 51 (depends on 50)

The vector of claim 50, wherein the linker sequence comprises Alanine and Tyrosine.

### Claim 52 (depends on 50)

The vector of claim 50, wherein the linker sequence comprises Glycine and Proline.

### Claim 53 (depends on 43)

The vector of claim 43, wherein the two or more highly networked HIV CTL epitopes are selected from the group consisting of HLA-A*02 YVDRFYKTL, HLA-A*02 PLTFGWCYKL, HLA-A*02 KLTPLCVTL, HLA-A*02 VIYQYMDDL, HLA-A*02 LVGPTPVNI, HLA-A*03 GIPHPAGLK, HLA-B*07 TPQDLNTML, HLA-B*07 SPRTLNAWV, HLA-B*07 TPGPGVRYPL, and HLA-B*40 SEGATPQDL.

### Claim 54 (depends on 43)

The vector of claim 43, wherein the vector comprises sequences encoding highly networked HIV CTL epitopes having at least 65% to about 99% homology to epitopes HLA-A*02 YVDRFYKTL, HLA-A*02 PLTFGWCYKL, HLA-A*02 KLTPLCVTL, HLA-A*02 VIYQYMDDL, HLA-A*02 LVGPTPVNI, HLA-A*03 GIPHPAGLK, HLA-B*07 TPQDLNTML, HLA-B*07 SPRTLNAWV, HLA-B*07 TPGPGVRYPL, and HLA-B*40 SEGATPQDL.

### Claim 55 (depends on 43)

The vector of claim 43, wherein the two or more highly networked HIV CTL epitopes are selected from the group consisting of HLA-A*01/A*29/B*35/B*57 YFPDWQNYT, HLA-A*02 YVDRFYKTL, HLA-A*02 PLTFGWCYKL, HLA-A*02 KLTPLCVTL, HLA-A*02 VIYQYMDDL, HLA-A*02 LVGPTPVNI, HLA-A*03 GIPHPAGLK, HLA-A*11 ACQGVGGPGHK, HLA-A*24 RDYVDRFYKTL, HLA-A*26 EVIPMFSAL, HLA-B*07 TPQDLNTML, HLA-B*07 SPRTLNAWV, HLA-B*07 TPGPGVRYPL, HLA-B*14 VRMYSPVSI, HLA-B*14 DRFYKTLRA, HLA-B*14 IRYQYNVL, HLA-B*1501 GLNKIVRMY, HLA-B*1510/B*3901 GHQAAMQML, HLA-B*18/B*53 YPLTFGWCY, HLA-B*27 TRYPLTFGW, HLA-B*27 KRKGGIGGY, HLA-B*27 KRWIILGLNK, HLA-B*40 SEGATPQDL, HLA-B*40 GERIVDII, HLA-B*44 EEKAFSPEV, HLA-B*44 AEQASQDVKNW, HLA-B*49 TWEAWWTEYW, HLA-B*51/Cw*03/Cw*15 RAIEAQQHL, HLA-B*53/B*57 QASQEVKNW, HLA-B*57 IAMESIVIW, HLA-B*57 ISPRTLNAW, HLA-B*57 KAFSPEVIPMF, HLA-B*81 TPVNIIGRNML, and HLA-Cw*08 IVTDSQYAL.

### Claim 56 (depends on 43)

The vector of claim 43, wherein the vector comprises sequences encoding highly networked HIV CTL epitopes having at least 65% to about 99% homology to epitopes HLA-A*01/A*29/B*35/B*57 YFPDWQNYT, HLA-A*02 YVDRFYKTL, HLA-A*02 PLTFGWCYKL, HLA-A*02 KLTPLCVTL, HLA-A*02 VIYQYMDDL, HLA-A*02 LVGPTPVNI, HLA-A*03 GIPHPAGLK, HLA-A*11 ACQGVGGPGHK, HLA-A*24 RDYVDRFYKTL, HLA-A*26 EVIPMFSAL, HLA-B*07 TPQDLNTML, HLA-B*07 SPRTLNAWV, HLA-B*07 TPGPGVRYPL, HLA-B*14 VRMYSPVSI, HLA-B*14 DRFYKTLRA, HLA-B*14 IRYQYNVL, HLA-B*1501 GLNKIVRMY, HLA-B*1510/B*3901 GHQAAMQML, HLA-B*18/B*53 YPLTFGWCY, HLA-B*27 TRYPLTFGW, HLA-B*27 KRKGGIGGY, HLA-B*27 KRWIILGLNK, HLA-B*40 SEGATPQDL, HLA-B*40 GERIVDII, HLA-B*44 EEKAFSPEV, HLA-B*44 AEQASQDVKNW, HLA-B*49 TWEAWWTEYW, HLA-B*51/Cw*03/Cw*15 RAIEAQQHL, HLA-B*53/B*57 QASQEVKNW, HLA-B*57 IAMESIVIW, HLA-B*57 ISPRTLNAW, HLA-B*57 KAFSPEVIPMF, HLA-B*81 TPVNIIGRNML, and HLA-Cw*08 IVTDSQYAL.

### Claim 57 (depends on 43)

The vector of claim 43, wherein the two or more highly networked HIV CTL epitopes are selected from the group consisting of HLA-E*101/HLA-E*103 SALSEGATP, HLA-E*101/HLA-E*103 VGGHQAAMQ, HLA-E*101/HLA-E*103 HQAISPRTL, HLA-E*101/HLA-E*103 RIRTWKSLV, HLA-E*101/HLA-E*103 RMYSPTSIL, HLA-E*101/HLA-E*103 AISPRTLNA, and HLA-E*101/HLA-E*103 STLQEQIGW.

### Claim 58 (depends on 43)

The vector of claim 43, wherein the vector comprises sequences encoding highly networked HIV CTL epitopes having at least 65% to about 99% homology to epitopes HLA-E*101/HLA-E*103 SALSEGATP, HLA-E*101/HLA-E*103 VGGHQAAMQ, HLA-E*101/HLA-E*103 HQAISPRTL, HLA-E*101/HLA-E*103 RIRTWKSLV, HLA-E*101/HLA-E*103 RMYSPTSIL, HLA-E*101/HLA-E*103 AISPRTLNA, HLA-E*101/HLA-E*103 STLQEQIGW.

### Claim 59 (depends on 43)

The vector of claim 43, wherein the two or more highly networked HIV CTL epitopes are selected from the group consisting of HLA-A*02 YVDRFYKTL, HLA-A*02 PLTFGWCYKL, HLA-A*02 KLTPLCVTL, HLA-A*02 VIYQYMDDL, HLA-A*02 LVGPTPVNI, HLA-A*03 GIPHPAGLK, HLA-B*07 TPQDLNTML, HLA-B*07 SPRTLNAWV, HLA-B*07 TPGPGVRYPL, HLA-B*40 SEGATPQDL, HLA-E*101/HLA-E*103 SALSEGATP, HLA-E*101/HLA-E*103 VGGHQAAMQ, HLA-E*101/HLA-E*103 HQAISPRTL, HLA-E*101/HLA-E*103 RIRTWKSLV, HLA-E*101/HLA-E*103 RMYSPTSIL, HLA-E*101/HLA-E*103 AISPRTLNA, and HLA-E*101/HLA-E*103 STLQEQIGW.

### Claim 60 (depends on 43)

The vector of claim 43, wherein the vector comprises sequences encoding highly networked HIV CTL epitopes having at least 65% to about 99% homology to epitopes HLA-A*02 YVDRFYKTL, HLA-A*02 PLTFGWCYKL, HLA-A*02 KLTPLCVTL, HLA-A*02 VIYQYMDDL, HLA-A*02 LVGPTPVNI, HLA-A*03 GIPHPAGLK, HLA-B*07 TPQDLNTML, HLA-B*07 SPRTLNAWV, HLA-B*07 TPGPGVRYPL, HLA-B*40 SEGATPQDL, HLA-E*101/HLA-E*103 SALSEGATP, HLA-E*101/HLA-E*103 VGGHQAAMQ, HLA-E*101/HLA-E*103 HQAISPRTL, HLA-E*101/HLA-E*103 RIRTWKSLV, HLA-E*101/HLA-E*103 RMYSPTSIL, HLA-E*101/HLA-E*103 AISPRTLNA, and HLA-E*101/HLA-E*103 STLQEQIGW.

### Claim 61 (depends on 43)

The vector of claim 43, wherein the two or more highly networked HIV CTL epitopes are selected from the group consisting of HLA-A*01/A*29/B*35/B*57 YFPDWQNYT, HLA-A*02 YVDRFYKTL, HLA-A*02 PLTFGWCYKL, HLA-A*02 KLTPLCVTL, HLA-A*02 VIYQYMDDL, HLA-A*02 LVGPTPVNI, HLA-A*03 GIPHPAGLK, HLA-A*11 ACQGVGGPGHK, HLA-A*24 RDYVDRFYKTL, HLA-A*26 EVIPMFSAL, HLA-B*07 TPQDLNTML, HLA-B*07 SPRTLNAWV, HLA-B*07 TPGPGVRYPL, HLA-B*14 VRMYSPVSI, HLA-B*14 DRFYKTLRA, HLA-B*14 IRYQYNVL, HLA-B*1501 GLNKIVRMY, HLA-B*1510/B*3901 GHQAAMQML, HLA-B*18/B*53 YPLTFGWCY, HLA-B*27 TRYPLTFGW, HLA-B*27 KRKGGIGGY, HLA-B*27 KRWIILGLNK, HLA-B*40 SEGATPQDL, HLA-B*40 GERIVDII, HLA-B*44 EEKAFSPEV, HLA-B*44 AEQASQDVKNW, HLA-B*49 TWEAWWTEYW, HLA-B*51/Cw*03/Cw*15 RAIEAQQHL, HLA-B*53/B*57 QASQEVKNW, HLA-B*57 IAMESIVIW, HLA-B*57 ISPRTLNAW, HLA-B*57 KAFSPEVIPMF, HLA-B*81 TPVNIIGRNML, HLA-Cw*08 IVTDSQYAL, HLA-E*101/HLA-E*103 SALSEGATP, HLA-E*101/HLA-E*103 VGGHQAAMQ, HLA-E*101/HLA-E*103 HQAISPRTL, HLA-E*101/HLA-E*103 RIRTWKSLV, HLA-E*101/HLA-E*103 RMYSPTSIL, HLA-E*101/HLA-E*103 AISPRTLNA, and HLA-E*101/HLA-E*103 STLQEQIGW.

### Claim 62 (depends on 43)

The vector of claim 43, wherein the vector comprises sequences encoding highly networked HIV CTL epitopes having at least 65% to about 99% homology to epitopes HLA-A*01/A*29/B*35/B*57 YFPDWQNYT, HLA-A*02 YVDRFYKTL, HLA-A*02 PLTFGWCYKL, HLA-A*02 KLTPLCVTL, HLA-A*02 VIYQYMDDL, HLA-A*02 LVGPTPVNI, HLA-A*03 GIPHPAGLK, HLA-A*11 ACQGVGGPGHK, HLA-A*24 RDYVDRFYKTL, HLA-A*26 EVIPMFSAL, HLA-B*07 TPQDLNTML, HLA-B*07 SPRTLNAWV, HLA-B*07 TPGPGVRYPL, HLA-B*14 VRMYSPVSI, HLA-B*14 DRFYKTLRA, HLA-B*14 IRYQYNVL, HLA-B*1501 GLNKIVRMY, HLA-B*1510/B*3901 GHQAAMQML, HLA-B*18/B*53 YPLTFGWCY, HLA-B*27 TRYPLTFGW, HLA-B*27 KRKGGIGGY, HLA-B*27 KRWIILGLNK, HLA-B*40 SEGATPQDL, HLA-B*40 GERIVDII, HLA-B*44 EEKAFSPEV, HLA-B*44 AEQASQDVKNW, HLA-B*49 TWEAWWTEYW, HLA-B*51/Cw*03/Cw*15 RAIEAQQHL, HLA-B*53/B*57 QASQEVKNW, HLA-B*57 IAMESIVIW, HLA-B*57 ISPRTLNAW, HLA-B*57 KAFSPEVIPMF, HLA-B*81 TPVNIIGRNML, HLA-Cw*08 IVTDSQYAL, HLA-E*101/HLA-E*103 SALSEGATP, HLA-E*101/HLA-E*103 VGGHQAAMQ, HLA-E*101/HLA-E*103 HQAISPRTL, HLA-E*101/HLA-E*103 RIRTWKSLV, HLA-E*101/HLA-E*103 RMYSPTSIL, HLA-E*101/HLA-E*103 AISPRTLNA, and HLA-E*101/HLA-E*103 STLQEQIGW.

### Claim 63 (depends on 54, 56, 58, 60)

The vector of any one of claims 54, 56, 58, 60, and 62, wherein the percent homology to the epitope sequence is 75% to 85%.

### Claim 64 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

A pharmaceutical composition comprising the vector of any one of claims 42 to 63.

### Claim 65 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

A method of preventing or treating an HIV infection in a subject, said method comprising administering the vector of any one of claims 42 to 63 to the subject.

### Claim 66 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

A cell expressing the vector of any one of claims 42 to 63.

### Claim 67 (depends on 66)

The cell of claim 66, wherein the cell is an antigen presenting cell.

### Claim 68 (depends on 66, 67)

The cell of claims 66 and 67, wherein the cell is a human cell.

### Claim 69 (depends on 66, 67, 68)

The cell of any one of claims 66 to 68, wherein the highly networked HIV CTL epitopes are restricted by one or more HLA alleles.

### Claim 70 (depends on 66, 67, 68, 69)

The cell of any one of claims 66 to 69, wherein the cell is obtained from a subject diagnosed with HIV or at risk for developing HIV.

### Claim 71 (depends on 66, 67, 68, 69, 70)

A composition comprising any one of the cells of claims 66-70.

### Claim 72 (depends on 66, 67, 68, 69, 70, 71)

A method comprising administering to a subject the cell of any one of claims 66 to 70 or the composition of claim 71.

### Claim 73 (depends on 72)

The method of claim 72, wherein the method involves treating an autoimmune disease.

### Claim 74 (depends on 73)

The method of claim 73, wherein the autoimmune disease is HIV.

### Claim 75

A polypeptide comprising two or more highly networked HIV CTL epitopes, wherein the two or more highly networked HIV CTL epitopes each have a network score of at least 3.04.

### Claim 76 (depends on 75)

A cell expressing the polypeptide of claim 75.

### Claim 77

A method comprising engineering a human cell to comprise, on its surface, at least two or more highly networked HIV CTL epitopes each having a network score of at least 3.06 as shown in FIG. 21 or 22; and administering the engineered cell to a subject.

### Claim 78 (depends on 77)

The method of claim 77, wherein the highly networked HIV CTL epitopes are restricted on the surface of the cell by one or more HLA alleles.

### Claim 79 (depends on 77, 78)

The method of claim 77 or 78, wherein the cell is an antigen presenting cell.

### Claim 80 (depends on 77, 78, 79)

The method of any one of claims 77-79, wherein the cell is a human cell.

### Claim 81

A method comprising administering a vector expressing at least two or more highly networked HIV CTL epitopes each having a network score of at least 3.06 as shown in FIG. 21 or 22; and administering the vector to the subject.

### Claim 82 (depends on 81)

The method of claim 81, wherein upon expression of the vector in a cell the highly networked HIV CTL epitopes are restricted on the surface of the cell by one or more HLA alleles.

### Claim 83 (depends on 81, 82)

The method of claim 81 or 82, wherein the cell is an antigen presenting cell.

### Claim 84 (depends on 81, 82, 83)

The method of any one of claims 81-83, wherein the cell is a human cell.
